References

The global burden and associated factors of ovarian cancer in 1990–2019: findings from the Global Burden of Disease Study 2019

2022 · External reference

Incidence and Mortality of Cancers in Female Genital Organs — China, 2022

10.46234/ccdcw2024.040 · 2024 · External reference

An umbrella review of socioeconomic status and cancer

2024 · External reference

Clinicopathologic and Genomic Analysis of TP53 -Mutated Endometrial Carcinomas

10.1158/1078-0432.ccr-20-4436 · 2021 · External reference

Homologous recombination proficiency in ovarian and breast cancer patients

2021 · External reference

The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study

2020 · External reference

Socioeconomic Burden of Ovarian Cancer in 11 Countries

2025 · External reference

Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007–2014

2020 · External reference

Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage

10.1093/jnci/djy071 · 2018 · External reference

Correction: Liquid biopsy in gynecological cancers: a translational framework from molecular insights to precision oncology and clinical practice

2025 · External reference

Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement

10.1097/01.ogx.0000534156.01931.80 · 2018 · External reference

Current and Emerging Strategies for Tubo-Ovarian Cancer Diagnostics

10.3390/diagnostics13213331 · 2023 · External reference

Liquid biopsy in cancer: current status, challenges and future prospects

2024 · External reference

Ovarian cancer detection by DNA methylation in cervical scrapings

2019 · External reference

Liquid Biopsy: Blood-Based Analyses of ctDNA and CTCs

10.1093/clinchem/hvab168 · 2021 · External reference

Towards Preanalytical Best Practices for Liquid Biopsy Studies: A BLOODPAC Landscape Analysis

10.1002/cpt.3416 · 2024 · External reference

Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis

10.1016/j.jmoldx.2020.05.006 · 2020 · External reference

Multi-analyte approach combining cfDNA sequencing and protein testing for early ovarian cancer detection

10.1016/j.isci.2025.112617 · 2025 · External reference

Clinical utility of various liquid biopsy samples for the early detection of ovarian cancer: a comprehensive review

2025 · External reference

Recommendations for Cell-Free DNA Assay Validations

10.1016/j.jmoldx.2023.09.004 · 2023 · External reference

Circulating Cell-Free DNA Methylation Profiles in the Early Detection of Ovarian Cancer: A Scoping Review of the Literature

2021 · External reference

Cell-free DNA fragmentomics in cancer

10.1016/j.ccell.2025.09.006 · 2025 · External reference

QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

10.7326/0003-4819-155-8-201110180-00009 · 2011 · External reference

REporting recommendations for tumour MARKer prognostic studies (REMARK)

10.1038/sj.bjc.6602678 · 2005 · External reference

Liquid Biopsy, ctDNA Diagnosis through NGS

2021 · External reference

Next-generation sequencing methodologies to detect low-frequency mutations: “Catch me if you can”

2023 · External reference

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA

2018 · External reference

Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients

10.1038/s41379-018-0158-8 · 2019 · External reference

Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues

10.1073/pnas.1601311113 · 2016 · External reference

Early detection, clinicopathological subtyping, and prognosis prediction for endometrial cancer patients using fragmentomics liquid biopsy assay

2025 · External reference

Fragmentomics features of ovarian cancer

10.1002/ijc.34981 · 2024 · External reference

Refined characterization of circulating tumor DNA through biological feature integration

2022 · External reference

Cell-free DNA end characteristics enable accurate and sensitive cancer diagnosis

2024 · External reference

Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients

10.1016/j.jmoldx.2018.07.005 · 2018 · External reference

Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer Patients

10.1158/1078-0432.ccr-24-3335 · 2025 · External reference

Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib

2021 · External reference

The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples

2024 · External reference

Circulating tumor cell isolation for cancer diagnosis and prognosis

10.1016/j.ebiom.2022.104237 · 2022 · External reference

Circulating tumor cells: from new biological insights to clinical practice

2024 · External reference

Gene expression profiling of single circulating tumor cells in ovarian cancer – Establishment of a multi-marker gene panel

10.1016/j.molonc.2016.04.002 · 2016 · External reference

The Role of Circulating Tumor Cells in Ovarian Cancer Dissemination

10.3390/cancers14246030 · 2022 · External reference

Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis

10.1016/j.ygyno.2021.02.024 · 2021 · External reference

Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis

2015 · External reference

Circulating tumour cells: The Good, the Bad and the Ugly

2023 · External reference

Exosomal microRNA biomarkers in ovarian cancer detection: systematic review and meta-analysis

10.1016/j.cca.2025.120771 · 2026 · External reference

OCaMIR—A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study

10.1158/1078-0432.ccr-21-0267 · 2021 · External reference

A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis

10.1038/s41416-022-01925-0 · 2022 · External reference

Circulating Exosomal miRNAs as Biomarkers in Epithelial Ovarian Cancer

10.3390/biomedicines9101433 · 2021 · External reference

Review on Strategies and Technologies for Exosome Isolation and Purification

2022 · External reference

A review of exosomal isolation methods: is size exclusion chromatography the best option?

10.3390/ijms21186466 · 2020 · External reference

Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy

10.1007/s00795-022-00338-5 · 2022 · External reference

Predict ovarian cancer by pairing serum miRNAs: Construct of single sample classifiers

2022 · External reference

Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review

2023 · External reference

A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA

10.1016/j.ygyno.2013.04.048 · 2013 · External reference

Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma

10.1093/clinchem/hvac020 · 2022 · External reference

Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application

2024 · External reference

Precision gynecologic oncology: circulating cell free DNA epigenomic analysis, artificial intelligence and the accurate detection of ovarian cancer

2022 · External reference

Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings

10.1158/1078-0432.ccr-16-0863 · 2017 · External reference

Performance of Liquid Biopsy-Based Multi-Omics Biomarkers for Early Detection of Gynecological Malignancies: A Prospective Study (PERCEIVE-I)

2025 · External reference

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

10.1016/j.annonc.2021.05.806 · 2021 · External reference

Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options

10.1177/03008916221133136 · 2022 · External reference

New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening

10.1016/j.ccell.2022.01.012 · 2022 · External reference

Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples

10.1016/j.ygyno.2025.10.003 · 2025 · External reference

Circulating tumor DNA in the diagnosis of ovarian cancer: a systematic review

2026 · External reference

Integration of ultrasonography and circulating tumor DNA analysis enhances early detection of asymptomatic ovarian cancer

10.5603/gpl.103762 · 2026 · External reference

Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer

10.3390/cancers13225731 · 2021 · External reference

Detection of endometrial cancer using tampon-based collection and methylated DNA markers

10.1016/j.ygyno.2023.04.014 · 2023 · External reference

DNA Methylation of Combined Gene Markers in Cytological Specimens for Endometrial Cancer Screening

10.1002/dc.70081 · 2026 · External reference

Liquid biopsy biomarkers in cervical cancer: A systematic review and meta-analysis

2025 · External reference

Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes

10.1158/1940-6207.capr-16-0138 · 2016 · External reference

Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer

10.1016/j.ygyno.2022.07.028 · 2022 · External reference

Liquid Biopsy Analysis of the EV-Associated Micro-RNA Signature in Vulvar Carcinoma May Benefit Disease Diagnosis and Prognosis

10.3390/cancers18030438 · 2026 · External reference

New Trends in the Detection of Gynecological Precancerous Lesions and Early-Stage Cancers

10.3390/cancers13246339 · 2021 · External reference

Applying low coverage whole genome sequencing to detect malignant ovarian mass

2021 · External reference

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

2016 · External reference

Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer

10.1016/j.ejca.2019.11.012 · 2020 · External reference

Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients

10.3390/genes15060750 · 2024 · External reference

Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer

10.1158/0008-5472.can-23-1429 · 2023 · External reference

Dynamic changes in TP53 mutated circulating tumor DNA predicts outcome of patients with high-grade ovarian carcinomas

10.1136/ijgc-2024-005581 · 2024 · External reference

Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival

10.1016/j.ejca.2021.03.006 · 2021 · External reference

Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?

10.1016/j.ygyno.2025.11.005 · 2026 · External reference

Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis

10.1136/ijgc-2024-005313 · 2024 · External reference

Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer

10.1002/ijc.33362 · 2020 · External reference

Liquid biopsy: current technology and clinical applications

2022 · External reference

The Role of Circulating Tumor DNA in Ovarian Cancer

10.3390/cancers16183117 · 2024 · External reference

Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer

10.1016/j.ygyno.2022.09.004 · 2022 · External reference

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer

2021 · External reference

Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study

2016 · External reference

Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer

2021 · External reference

Sensitive circulating tumor DNA–based residual disease detection in epithelial ovarian cancer

2024 · External reference

Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies

10.1016/j.ygyno.2023.12.025 · 2024 · External reference

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

10.1158/2159-8290.cd-18-0715 · 2019 · External reference

Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer

10.1200/jco.2016.70.4627 · 2017 · External reference

Noninvasive detection of microsatellite instability in patients with endometrial cancer

10.1002/ijc.34435 · 2023 · External reference

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

10.1158/1078-0432.ccr-19-1324 · 2019 · External reference

Tumor Mutational Burden in Cervical Cancer as Potential Marker for Immunotherapy Responders

2025 · External reference

Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer

10.3390/cancers14153697 · 2022 · External reference

Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis

2015 · External reference

Liquid Biopsy for Monitoring EC Patients: Towards Personalized Treatment

10.3390/cancers14061405 · 2022 · External reference

Epigenetic Alteration by DNA Methylation of ESR1, MYOD1 and hTERT Gene Promoters is Useful for Prediction of Response in Patients of Locally Advanced Invasive Cervical Carcinoma Treated by Chemoradiation

10.1016/j.clon.2015.08.001 · 2015 · External reference

A microRNA expression signature for clinical response in locally advanced cervical cancer

10.1016/j.ygyno.2016.07.093 · 2016 · External reference

Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers

2018 · External reference

Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial

10.1016/j.ygyno.2024.12.004 · 2025 · External reference

Prognostic value of perioperative circulating tumor DNA in endometrial cancer: systematic review & meta-analysis

10.1016/j.ygyno.2025.12.008 · 2026 · External reference

Prognostic significance of circulating tumor DNA detection and quantification in cervical cancer: a systematic review and meta-analysis

2025 · External reference

Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses

10.1016/j.annonc.2025.05.533 · 2025 · External reference

The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer

10.1016/j.ygyno.2024.11.002 · 2025 · External reference

Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer

10.1200/jco.23.00954 · 2024 · External reference

Prognostic value of human papillomavirus cell-free DNA in cervical cancer patients: A systematic review and meta-analysis

10.5772/intechopen.107755 · 2024 · External reference

Identification and Validation of a Novel Multiomics Signature for Prognosis and Immunotherapy Response of Endometrial Carcinoma

2022 · External reference

Concordance of Genomic Alterations in Ovarian Cancer Tissues and Circulating-Tumor DNA: A Pilot Study

10.3390/ijms27031305 · 2026 · External reference

Liquid biopsies for the front line therapy decision in non-small cell lung cancer

10.1200/jco.2021.39.15_suppl.e21103 · 2021 · External reference

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)

10.1016/j.cllc.2022.11.007 · 2023 · External reference

Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions

10.1007/s40291-019-00442-w · 2019 · External reference

Cost-effectiveness assessment of liquid biopsy for early detection of lung cancer in Brazil

2025 · External reference

Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients

2024 · External reference

Direct detection of early-stage cancers using circulating tumor DNA

2017 · External reference

Unresolved reference

2024 · External reference

Socioeconomic impact of artificial intelligence–driven point-of-care testing devices for liquid biopsy in the OncoCheck system

2025 · External reference

Smart biosensors for multiplexed and fully integrated point-of-care diagnostics

10.1039/c6lc90046a · 2016 · External reference

Digital sensing technologies in cancer care: A new era in early detection and personalized diagnosis

2025 · External reference

Single-cell low-pass whole genome sequencing accurately detects circulating tumor cells for liquid biopsy-based multi-cancer diagnosis

2024 · External reference

An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples

2025 · External reference

A large-scale, multi-centre validation study of an AI-empowered blood-based test for multi-cancer early detection

2025 · External reference

Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study

10.1016/s0140-6736(23)01700-2 · 2023 · External reference

Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers

2015 · External reference